51 – 60 of 149
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
β-Amyloid-Dependent and-Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages : Implications for Clinical Alzheimer Trials
(
- Contribution to journal › Article
-
Mark
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
(
- Contribution to journal › Article
-
Mark
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau
(
- Contribution to journal › Article
-
Mark
Blood-based biomarkers for Alzheimer's disease
(
- Contribution to journal › Scientific review
- 2021
-
Mark
Biomarker testing in MCI patients—deciding who to test
(
- Contribution to journal › Article
-
Mark
Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays
(
- Contribution to journal › Article
-
Mark
Spatial Distribution of Tau and β-Amyloid Pathologies and Their Role in Different Alzheimer Disease Phenotypes
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease
(
- Contribution to journal › Article